A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales Abstract #1835

Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.
Aim(s): This prospective study evaluates the impact of GI assessment, investigation and management on quality of life(QOL) and GI symptoms upon establishing gastroenterology services to an endocrine/oncology NET service.
Materials and methods: Patients with a proven NET referred to the GI NET clinic in South East Wales were prospectively selected.Patients completed 2 questionnaires at baseline:gastrointestinal symptom rating scale (GSRS) and the GINET21 questionnaire. After GI investigation and management, patients were asked to complete questionnaires again.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr Mohid Khan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...
#1837 Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours
Introduction: There is limited data on exocrine pancreatic insufficiency in patients on somatostatin analogues(SSA) which affects quality of life in NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Mohid Khan
#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors
Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg